These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 29895706)

  • 1. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
    Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
    Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
    [No Abstract]   [Full Text] [Related]  

  • 2. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
    Zhang XY; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial.
    Li T; Dong Y; Wei Y; Wang S; Liu Y; Chen J; Xiong W; Lin N; Huang X; Liu M; Yan X; Ye Z; Li B
    Clin Cancer Res; 2024 Oct; 30(19):4310-4317. PubMed ID: 38483309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
    J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
    Mir O; Azaro A; Merchan J; Chugh R; Trent J; Rodon J; Ohnmacht U; Diener JT; Smith C; Yuen E; Oakley GJ; Le Cesne A; Soria JC; Benhadji KA; Massard C
    Eur J Cancer; 2018 Nov; 103():88-97. PubMed ID: 30218977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
    Cai M; Zhu J; Zhou G
    Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer.
    Li L; Liu W; Wang Y; Zhang Q; Chi C; Bai Q; Xu C; Yang R
    J Chemother; 2021 Nov; 33(7):492-498. PubMed ID: 33818318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study.
    Li ZK; Liu J; Deng YT; Jiang Y
    Anticancer Drugs; 2021 Feb; 32(2):210-214. PubMed ID: 33290314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
    Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
    Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
    J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.